Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Director Juan R. Luciano acquired 16 shares of Eli Lilly common stock through a deferral plan, at a price of $923.54 per share.

Summary

• Juan R. Luciano, a director at Eli Lilly & Co, acquired 16 shares of common stock on September 16, 2024.
• The shares were acquired at a price of $923.54 each.
• This acquisition was made through the Lilly Directors' Deferral Plan, where the shares are deferred in lieu of cash compensation.
• The shares will be settled in common stock after Luciano's separation from service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to slightly positive as it aligns director interests with shareholders.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the director's separation from service.

Industry Context

This is a routine filing related to director compensation and is common practice for publicly traded companies.

Comparison to Industry Standards

• Director share acquisitions through deferral plans are a common practice among publicly traded companies, including pharmaceutical companies like Pfizer (PFE) and Merck (MRK).
• These plans are often used to align the interests of directors with those of shareholders.
• The specific terms of deferral plans can vary, but the general concept of deferring compensation into company stock is widely used.

Stakeholder Impact

• The acquisition of shares by a director can be seen positively by shareholders as it indicates confidence in the company's future performance.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, Stock Units, LLY, Insider Trading